Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase

Jackie L. Martin, J. Gerald Kenna, Brian M. Martin, David Thomassen, George F. Reed, Lance R. Pohl

Research output: Contribution to journalArticle

Abstract

Clinical and laboratory evidence suggests that the fulminant liver failure sometimes associated with the inhalation anesthetic halothane may be an immunemediated toxicity. Most importantly, the vast majority of patients with a clinical diagnosis of halothane hepatitis have serum antibodies, which react with one or more specific liver microsomal proteins that have been covalently altered by the trifluoroacetyl chloride metabolite of halothane. The serum antibodies are specific to halothane hepatitis patients and are not seen in sera of patients with other types of liver pathology. In this study, a 57-kD trifluoroacetylated liver microsomal neoantigen associated with halothane hepatitis and native 57-kD protein were purified from liver microsomes of halothane-treated and -untreated rats, respectively. When the purified trifluoroacetylated 57-kD and native 57-kD proteins were used as test antigens in an enzyme-linked immunosorbent assay, serum antibodies from halothane hepatitis patients (n = 40) reacted with both of these proteins to a significantly greater extent than did serum antibodies from control patients (n = 32). On the basis of its apparent monomeric molecular mass, isoelectric point and NH2-terminal amino acid and tryptic peptide sequences, the 57-kD protein has been identified as rat liver protein disulfide isomerase. Antibodies raised against rat liver protein disulfide isomerase also reacted with a protein of approximately 58-kD in human liver microsomes. The results of this investigation suggest that trifluoroacetylated protein disulfide isomerase is one of the immunogens associated with halothane hepatitis. In certain patients it might lead either to specific antibodies or, possibly, to specific T cells, which could be responsible for halothane hepatitis.

Original languageEnglish (US)
Pages (from-to)858-863
Number of pages6
JournalHepatology
Volume18
Issue number4
StatePublished - Oct 1993

Fingerprint

Protein Disulfide-Isomerases
Antibodies
Halothane
Serum
Liver
Proteins
Liver Microsomes
Inhalation Anesthetics
Acute Liver Failure
Isoelectric Point
Halothane Hepatitis
Enzyme-Linked Immunosorbent Assay
Pathology
T-Lymphocytes
Antigens
Amino Acids
Peptides

ASJC Scopus subject areas

  • Hepatology

Cite this

Martin, J. L., Kenna, J. G., Martin, B. M., Thomassen, D., Reed, G. F., & Pohl, L. R. (1993). Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. Hepatology, 18(4), 858-863.

Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. / Martin, Jackie L.; Kenna, J. Gerald; Martin, Brian M.; Thomassen, David; Reed, George F.; Pohl, Lance R.

In: Hepatology, Vol. 18, No. 4, 10.1993, p. 858-863.

Research output: Contribution to journalArticle

Martin, JL, Kenna, JG, Martin, BM, Thomassen, D, Reed, GF & Pohl, LR 1993, 'Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase', Hepatology, vol. 18, no. 4, pp. 858-863.
Martin JL, Kenna JG, Martin BM, Thomassen D, Reed GF, Pohl LR. Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. Hepatology. 1993 Oct;18(4):858-863.
Martin, Jackie L. ; Kenna, J. Gerald ; Martin, Brian M. ; Thomassen, David ; Reed, George F. ; Pohl, Lance R. / Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. In: Hepatology. 1993 ; Vol. 18, No. 4. pp. 858-863.
@article{ce9a79b55d2b4e96976f608a5a74f1dd,
title = "Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase",
abstract = "Clinical and laboratory evidence suggests that the fulminant liver failure sometimes associated with the inhalation anesthetic halothane may be an immunemediated toxicity. Most importantly, the vast majority of patients with a clinical diagnosis of halothane hepatitis have serum antibodies, which react with one or more specific liver microsomal proteins that have been covalently altered by the trifluoroacetyl chloride metabolite of halothane. The serum antibodies are specific to halothane hepatitis patients and are not seen in sera of patients with other types of liver pathology. In this study, a 57-kD trifluoroacetylated liver microsomal neoantigen associated with halothane hepatitis and native 57-kD protein were purified from liver microsomes of halothane-treated and -untreated rats, respectively. When the purified trifluoroacetylated 57-kD and native 57-kD proteins were used as test antigens in an enzyme-linked immunosorbent assay, serum antibodies from halothane hepatitis patients (n = 40) reacted with both of these proteins to a significantly greater extent than did serum antibodies from control patients (n = 32). On the basis of its apparent monomeric molecular mass, isoelectric point and NH2-terminal amino acid and tryptic peptide sequences, the 57-kD protein has been identified as rat liver protein disulfide isomerase. Antibodies raised against rat liver protein disulfide isomerase also reacted with a protein of approximately 58-kD in human liver microsomes. The results of this investigation suggest that trifluoroacetylated protein disulfide isomerase is one of the immunogens associated with halothane hepatitis. In certain patients it might lead either to specific antibodies or, possibly, to specific T cells, which could be responsible for halothane hepatitis.",
author = "Martin, {Jackie L.} and Kenna, {J. Gerald} and Martin, {Brian M.} and David Thomassen and Reed, {George F.} and Pohl, {Lance R.}",
year = "1993",
month = "10",
language = "English (US)",
volume = "18",
pages = "858--863",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase

AU - Martin, Jackie L.

AU - Kenna, J. Gerald

AU - Martin, Brian M.

AU - Thomassen, David

AU - Reed, George F.

AU - Pohl, Lance R.

PY - 1993/10

Y1 - 1993/10

N2 - Clinical and laboratory evidence suggests that the fulminant liver failure sometimes associated with the inhalation anesthetic halothane may be an immunemediated toxicity. Most importantly, the vast majority of patients with a clinical diagnosis of halothane hepatitis have serum antibodies, which react with one or more specific liver microsomal proteins that have been covalently altered by the trifluoroacetyl chloride metabolite of halothane. The serum antibodies are specific to halothane hepatitis patients and are not seen in sera of patients with other types of liver pathology. In this study, a 57-kD trifluoroacetylated liver microsomal neoantigen associated with halothane hepatitis and native 57-kD protein were purified from liver microsomes of halothane-treated and -untreated rats, respectively. When the purified trifluoroacetylated 57-kD and native 57-kD proteins were used as test antigens in an enzyme-linked immunosorbent assay, serum antibodies from halothane hepatitis patients (n = 40) reacted with both of these proteins to a significantly greater extent than did serum antibodies from control patients (n = 32). On the basis of its apparent monomeric molecular mass, isoelectric point and NH2-terminal amino acid and tryptic peptide sequences, the 57-kD protein has been identified as rat liver protein disulfide isomerase. Antibodies raised against rat liver protein disulfide isomerase also reacted with a protein of approximately 58-kD in human liver microsomes. The results of this investigation suggest that trifluoroacetylated protein disulfide isomerase is one of the immunogens associated with halothane hepatitis. In certain patients it might lead either to specific antibodies or, possibly, to specific T cells, which could be responsible for halothane hepatitis.

AB - Clinical and laboratory evidence suggests that the fulminant liver failure sometimes associated with the inhalation anesthetic halothane may be an immunemediated toxicity. Most importantly, the vast majority of patients with a clinical diagnosis of halothane hepatitis have serum antibodies, which react with one or more specific liver microsomal proteins that have been covalently altered by the trifluoroacetyl chloride metabolite of halothane. The serum antibodies are specific to halothane hepatitis patients and are not seen in sera of patients with other types of liver pathology. In this study, a 57-kD trifluoroacetylated liver microsomal neoantigen associated with halothane hepatitis and native 57-kD protein were purified from liver microsomes of halothane-treated and -untreated rats, respectively. When the purified trifluoroacetylated 57-kD and native 57-kD proteins were used as test antigens in an enzyme-linked immunosorbent assay, serum antibodies from halothane hepatitis patients (n = 40) reacted with both of these proteins to a significantly greater extent than did serum antibodies from control patients (n = 32). On the basis of its apparent monomeric molecular mass, isoelectric point and NH2-terminal amino acid and tryptic peptide sequences, the 57-kD protein has been identified as rat liver protein disulfide isomerase. Antibodies raised against rat liver protein disulfide isomerase also reacted with a protein of approximately 58-kD in human liver microsomes. The results of this investigation suggest that trifluoroacetylated protein disulfide isomerase is one of the immunogens associated with halothane hepatitis. In certain patients it might lead either to specific antibodies or, possibly, to specific T cells, which could be responsible for halothane hepatitis.

UR - http://www.scopus.com/inward/record.url?scp=0027685774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027685774&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 858

EP - 863

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -